It may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called “ nonsquamous” and your tumor does not have an abnormal “EGFR” or “ALK” gene.a kind of lung cancer called non–small cell lung cancer (NSCLC).It may be used in adults and children 12 years of age and older with stage IIB, stage IIC, or stage III melanoma, to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.It may be used when your melanoma has spread or cannot be removed by surgery (advanced melanoma), or.It may be used with chemotherapy medicines when your breast cancer has returned and cannot be removed by surgery or has spread (advanced TNBC), and tests positive for “PD-L1.”.It may be used with chemotherapy medicines as treatment before surgery and then continued alone after surgery when you have early-stage breast cancer, and are at high risk of your breast cancer coming back (high-risk early-stage triple-negative breast cancer ).a kind of cancer called triple-negative breast cancer (TNBC).following at least two prior therapies when ASCT or multi‑agent chemotherapy is not a treatment option.ĪDCETRIS in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) (see section 5.1).ĪDCETRIS is indicated for the treatment of adult patients with relapsed or refractory sALCL.ĪDCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T‑cell lymphoma (CTCL) after at least 1 prior systemic therapy (see section 5.1).ĭetailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.KEYTRUDA is a prescription medicine used to treat:.
Cutaneous tcel lymphoma full#
For information, the full indications for Adcetris will be as follows: 1ĪDCETRIS is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) (see sections 4.2 and 5.1).ĪDCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT) (see section 5.1).ĪDCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): The CHMP adopted an extension to an existing indication to include treatment of Stage III Hodgkin lymphoma (HL). The marketing authorisation holder for this medicinal product is Takeda Pharma A/S. On 14 September 2023, the Committee for Medicinal Products for Human Use ( CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Adcetris.
0 kommentar(er)
